LifeStance (LFST) Insider Files Form 144 to Sell 226,518 Shares
Rhea-AI Filing Summary
LifeStance Health Group, Inc. (LFST) filed a Form 144 reporting a proposed sale of 226,518 shares of common stock through Morgan Stanley & Co. LLC on 08/18/2025. The filing states an aggregate market value of $1,225,462.38 and reports 388,936,394 shares outstanding. The securities were acquired in a pre-IPO transaction on 06/10/2021, when 1,299,792 shares were obtained from the issuer; payment is noted as equity interests purchased pre-IPO. No sales by the reporting person in the past three months are disclosed. The filer certifies they are unaware of undisclosed material adverse information about the issuer.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider plans a routine secondary sale of 226,518 shares; size appears small relative to shares outstanding.
The Form 144 documents a proposed brokered sale of 226,518 common shares valued at $1.23 million on 08/18/2025 via Morgan Stanley. The position originated from a pre-IPO acquisition on 06/10/2021 totaling 1,299,792 shares. With 388,936,394 shares outstanding, the proposed sale represents a small percentage of the float, indicating this is likely a routine disposition rather than a material event for the company. The filing also confirms no related sales in the prior three months and includes the standard attestation regarding undisclosed material adverse information.
TL;DR: Disclosure follows Rule 144 mechanics; documentation shows pre-IPO origin and brokered execution.
The notice provides required Rule 144 details: acquisition date, nature of acquisition (pre-IPO), broker name and address, number of shares offered, and aggregate market value. The signer affirms lack of undisclosed material information and indicates no recent sales by the reporting person. From a governance perspective, the filing appears procedurally complete and compliant with Form 144 presentation requirements.